{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:29Z","timestamp":1787070869813,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Extranodal (EN) involvement in diffuse large B-cell lymphoma (DLBCL) carries poor prognosis. Both the number and the specific sites of EN involvement are important in predicting prognosis. Given that the epidemiologic pattern of DLBCL in India is different from the rest of the world and such data correlations are scarce from developing countries, we aimed to find out if specific site and number of EN involvement could predict survival in DLBCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients with DLBCL treated with combination chemotherapy plus rituximab were included. Site and number of EN involvement were noted. Univariate analysis for survival was performed for EN involvement or not, specific site of involvement, and number of EN involvement (0\/1 vs. \u22652).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among a total of 177 patients, 92 (52%) patients had EN disease. When patients with 2 or more EN sites were compared against patients with 0 or 1 site, there was significant reduction in both progression-free survival (PFS) and overall survival (OS) (3-year OS of 55% vs. 79%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001, 3-year PFS of 42% vs. 65%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). When specific EN sites were studied for correlation with survival, involvement of skin\/soft tissue, and serosa were associated with significant reduction in 3-year OS (33% vs. 74%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.011, and 63% vs. 75%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03, respectively) and 3-year PFS (25% vs. 62%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001, and 46% vs. 62%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Two or more EN sites in DLBCL predicted inferior survival. Serosal and skin\/soft tissue involvement also predicted poor survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_428_19","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T07:27:42Z","timestamp":1631777262000},"page":"938-942","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Pattern of extranodal involvement and its impact on survival in diffuse large B-cell lymphoma from a tertiary cancer center in rural India"],"prefix":"10.4103","volume":"17","author":[{"given":"Chandran K.","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju R.","family":"Kurup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Manuprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen Kumar","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineetha","family":"Raghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20241021","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-18-20241021","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000447577","article-title":"Epidemiology of non-Hodgkin's lymphoma in India","volume":"91","author":"Nair","year":"2016","journal-title":"Oncology"},{"key":"R3-18-20241021","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4103\/sajc.sajc_60_18","article-title":"Profile of non-Hodgkin lymphoma: An Indian perspective","volume":"7","author":"Gogia","year":"2018","journal-title":"South Asian J Cancer"},{"key":"R4-18-20241021","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2141.2003.04749.x","article-title":"Diffuse large B-cell lymphoma: Clinical implications of extranodal versus nodal presentation \u2013 A population-based study of 1575 cases","volume":"124","author":"M\u00f8ller","year":"2004","journal-title":"Br J Haematol"},{"key":"R5-18-20241021","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3109\/10428194.2010.504872","article-title":"Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"51","author":"Hui","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"R7-18-20241021","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/ajh.24169","article-title":"Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET\/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"key":"R8-18-20241021","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"R9-18-20241021","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.hemonc.2018.07.005","article-title":"BCL-2 overexpression overcomes cell of origin stratification in diffuse large B-cell lymphoma","volume":"12","author":"Damlaj","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R10-18-20241021","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"R11-18-20241021","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/annonc\/11.suppl_1.S63","article-title":"Distribution of various subtypes of non-Hodgkin's lymphoma in India: A study of 2773 lymphomas using R.E.A.L. and WHO Classifications","volume":"11","author":"Naresh","year":"2000","journal-title":"Ann Oncol"},{"key":"R12-18-20241021","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3904\/kjim.2010.25.3.301","article-title":"Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma","volume":"25","author":"Yoo","year":"2010","journal-title":"Korean J Intern Med"},{"key":"R13-18-20241021","doi-asserted-by":"crossref","first-page":"57","DOI":"10.21147\/j.issn.1000-9604.2017.01.07","article-title":"Extranodal involvement in young patients with diffuse large B-cell lymphoma: Distribution, prognostic value and treatment options","volume":"29","author":"Yao","year":"2017","journal-title":"Chin J Cancer Res"},{"key":"R14-18-20241021","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/carcin\/bgr066","article-title":"Interactions among genes, tumor biology and the environment in cancer health disparities: Examining the evidence on a national and global scale","volume":"32","author":"Wallace","year":"2011","journal-title":"Carcinogenesis"},{"key":"R15-18-20241021","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/10428190701809156","article-title":"Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab","volume":"49","author":"Ngo","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R16-18-20241021","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J Clin Oncol"},{"key":"R17-18-20241021","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3109\/10428194.2014.982636","article-title":"Diffuse large B-cell lymphoma: Sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era","volume":"56","author":"Lu","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R18-18-20241021","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00277-016-2689-8","article-title":"A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy","volume":"95","author":"Hwang","year":"2016","journal-title":"Ann Hematol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_428_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:56Z","timestamp":1787067476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_428_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_428_19","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}